← Leaderboards
Sergei S Makarov
University Of North Carolina Chapel Hill
$20,211,957
Attributed
$21,711,956
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,711,956 · 10
By mechanism
U01$11,467,383 · 1
R44$7,990,155 · 4
R01$1,050,774 · 2
P60$737,861 · 1
R43$465,783 · 2
Top collaborators
- Nicholas Hunter Oberlies3 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Albert Sidney Baldwin$25,224,800
- Melissa E. Derosier$17,731,014
- Kuo-Hsiung Lee$16,683,783
- Michael T. Crimmins$6,748,855
- Jian None Liu$13,658,713
Others in their field
Top investigators on “Nuclear Factor Kappa Beta”
- Inder Mohan Verma · Salk Institute For Biological Studies$6,196,441
- Dongsheng Cai · University Of Wisconsin-Madison$5,730,216
- Albert Sidney Baldwin · University Of North Carolina Chapel Hill$5,313,928
- Yvonne M.w. Janssen-Heininger · University Of Vermont &St Agric College$5,184,302
- Michael Karin · University Of California, San Diego$5,001,646
- Cun-Yu Wang · University Of California Los Angeles$3,982,945
Research focus
Nuclear Factor Kappa BetaResponseSynovial MembraneLaboratory RatTranscription FactorRheumatoid ArthritisCellsTechnologyPathway InteractionsPharmaceutical PreparationsGenesInflammationEvaluationStructureBiological Signal TransductionCollectionReporterGeneticGene ExpressionSignal PathwayScreeningApoptosisCostCollaborations
Grant awards (26)
A Two-Tier Effect-Based Water Bioactivity Surveillance System.$999,999
R44 · FY2025 · ES · contact PI
Assigning mode of action to phenotypically discovered anticancer leads.$1,000,000
R44 · FY2024 · CA · contact PI
Assigning mode of action to phenotypically discovered anticancer leads.$1,000,000
R44 · FY2023 · CA · contact PI
Assessing the polypharmacology of kinase inhibitors by transcription factor activity profiling$999,998
R44 · FY2021 · GM · contact PI
Assessing the polypharmacology of kinase inhibitors by transcription factor activity profiling$999,998
R44 · FY2020 · GM · contact PI
Predicting DILI liability by transcription factor profiling$707,364
R44 · FY2019 · GM · contact PI
Predicting DILI liability by transcription factor profiling$1,025,137
R44 · FY2018 · GM · contact PI
Predicting DILI liability by transcription factor profiling$241,510
R44 · FY2018 · GM · contact PI
Predicting DILI liability by transcription factor profiling$1,016,149
R44 · FY2017 · GM · contact PI
Identification of TLR signaling network$2,325,818
U01 · FY2008 · AI · contact PI
Identification of TLR signaling network$2,326,024
U01 · FY2007 · AI · contact PI
Identification of TLR signaling network$2,352,579
U01 · FY2006 · AI · contact PI
Identification of TLR signaling network$2,242,952
U01 · FY2005 · AI
Identification of TLR signaling network$2,220,010
U01 · FY2004 · AI
Novel biosensors for toxicological applications$320,149
R43 · FY2004 · CA
Profiling of signal transduction pathways in cancer$145,634
R43 · FY2004 · CA
IMMUNOSUPPRESSIVE GENE THERAPY FOR RA$224,647
R01 · FY2003 · AI
IMMUNOSUPPRESSIVE GENE THERAPY FOR RA$192,527
R01 · FY2002 · AI
SIGNALING PATHWAYS CONTROLLING NF-KB IN RHEUMATIOID ARTHRITIS$139,725
P60 · FY2002 · DE
SIGNALING PATHWAYS CONTROLLING NF-KB IN RHEUMATIOID ARTHRITIS$139,725
P60 · FY2002 · DE
IMMUNOSUPPRESSIVE GENE THERAPY FOR RA$211,755
R01 · FY2001 · AI
SIGNALING PATHWAYS CONTROLLING NF-KB IN RHEUMATIOID ARTHRITIS$139,725
P60 · FY2001 · DE
NOVEL TARGETS FOR GENE THERAPY OF ARTHRITIS$216,262
R01 · FY2000 · AR
IMMUNOSUPPRESSIVE GENE THERAPY FOR RA$205,583
R01 · FY2000 · AI
SIGNALING PATHWAYS CONTROLLING NF-KB IN RHEUMATIOID ARTHRITIS$201,903
P60 · FY2000 · DE
SIGNALING PATHWAYS CONTROLLING NF-KB IN RHEUMATIOID ARTHRITIS$116,783
P60 · FY2000 · DE